PDF(Pubmed)
Abstract：
This case report explores the efficacy of warfarin compared to apixaban in managing antiphospholipid syndrome (APS), an autoimmune disorder characterized by recurrent thrombosis. We emphasize the constraints of direct oral anticoagulants (DOACs) such as apixaban in APS management. This case discusses a 41-year-old female patient with APS who did not respond to apixaban therapy. The report details her transition to warfarin, resulting in symptom resolution and no further complications, thus alluding to warfarin\'s effectiveness in APS management over apixaban. The case contributes to the ongoing debate on the suitability of modern DOACs in APS treatment.
摘要：
本病例报告探讨了华法林与阿哌沙班相比治疗抗磷脂综合征（APS）的疗效。一种以反复血栓形成为特征的自身免疫性疾病。我们强调阿哌沙班等直接口服抗凝剂（DOAC）在APS管理中的局限性。该病例讨论了一名41岁的APS女性患者，该患者对阿哌沙班治疗无反应。报告详细介绍了她向华法林的过渡,导致症状缓解，没有进一步的并发症，因此暗示华法林在APS管理中的有效性优于阿哌沙班。此案有助于有关现代DOAC在APS治疗中的适用性的持续辩论。
